Trade Alnylam Pharmaceuticals, Inc. - ALNY CFD
Add to favourite- Summary
- Historical Data
| Spread | 1.45 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 230.44 |
| Open | 230.63 |
| 1-Year Change | 57.43% |
| Day's Range | 228.62 - 234.26 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 234.26 | 4.35 | 1.89% | 229.91 | 234.96 | 228.04 |
| Apr 16, 2025 | 230.44 | -0.45 | -0.19% | 230.89 | 233.75 | 225.62 |
| Apr 15, 2025 | 230.65 | -8.30 | -3.47% | 238.95 | 241.33 | 227.73 |
| Apr 14, 2025 | 239.83 | 1.50 | 0.63% | 238.33 | 240.88 | 232.82 |
| Apr 11, 2025 | 237.49 | 15.19 | 6.83% | 222.30 | 239.84 | 221.64 |
| Apr 10, 2025 | 225.80 | -5.26 | -2.28% | 231.06 | 232.70 | 213.55 |
| Apr 9, 2025 | 241.56 | 19.97 | 9.01% | 221.59 | 244.12 | 205.45 |
| Apr 8, 2025 | 224.26 | -16.59 | -6.89% | 240.85 | 243.46 | 220.47 |
| Apr 7, 2025 | 232.81 | 8.65 | 3.86% | 224.16 | 237.26 | 219.95 |
| Apr 4, 2025 | 235.52 | -21.81 | -8.48% | 257.33 | 257.33 | 235.49 |
| Apr 3, 2025 | 262.10 | -1.14 | -0.43% | 263.24 | 263.81 | 257.08 |
| Apr 2, 2025 | 266.74 | 14.24 | 5.64% | 252.50 | 267.07 | 252.50 |
| Apr 1, 2025 | 254.90 | -16.46 | -6.07% | 271.36 | 271.75 | 254.90 |
| Mar 31, 2025 | 269.40 | 6.45 | 2.45% | 262.95 | 271.17 | 257.94 |
| Mar 28, 2025 | 268.16 | -0.74 | -0.28% | 268.90 | 270.68 | 263.86 |
| Mar 27, 2025 | 270.36 | 2.48 | 0.93% | 267.88 | 275.23 | 263.50 |
| Mar 26, 2025 | 267.51 | -12.41 | -4.43% | 279.92 | 280.34 | 267.51 |
| Mar 25, 2025 | 280.20 | -6.11 | -2.13% | 286.31 | 292.13 | 280.20 |
| Mar 24, 2025 | 288.93 | 0.98 | 0.34% | 287.95 | 300.21 | 287.09 |
| Mar 21, 2025 | 283.02 | 19.82 | 7.53% | 263.20 | 288.56 | 260.35 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Alnylam Company profile
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
675 W Kendall St
CAMBRIDGE
MASSACHUSETTS 02142-1168
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com